- Home
- TNXP vs VWAV Comparison
TNXP vs VWAV Comparison
Compare TNXP & VWAV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNXP
- VWAV
- Stock Information
- Founded
- TNXP 2007
- VWAV 2024
- Country
- TNXP United States
- VWAV United States
- Employees
- TNXP N/A
- VWAV N/A
- Industry
- TNXP Biotechnology: Pharmaceutical Preparations
- VWAV Computer Software: Prepackaged Software
- Sector
- TNXP Health Care
- VWAV Technology
- Exchange
- TNXP Nasdaq
- VWAV Nasdaq
- Market Cap
- TNXP 173.9M
- VWAV 162.2M
- IPO Year
- TNXP N/A
- VWAV N/A
- Fundamental
- Price
- TNXP $18.49
- VWAV $11.96
- Analyst Decision
- TNXP Buy
- VWAV
- Analyst Count
- TNXP 1
- VWAV 0
- Target Price
- TNXP $70.00
- VWAV N/A
- AVG Volume (30 Days)
- TNXP 851.8K
- VWAV 360.3K
- Earning Date
- TNXP 11-07-2025
- VWAV 11-26-2025
- Dividend Yield
- TNXP N/A
- VWAV N/A
- EPS Growth
- TNXP N/A
- VWAV N/A
- EPS
- TNXP N/A
- VWAV N/A
- Revenue
- TNXP $9,831,000.00
- VWAV N/A
- Revenue This Year
- TNXP $14.79
- VWAV N/A
- Revenue Next Year
- TNXP $933.49
- VWAV N/A
- P/E Ratio
- TNXP N/A
- VWAV N/A
- Revenue Growth
- TNXP N/A
- VWAV N/A
- 52 Week Low
- TNXP $6.76
- VWAV $2.06
- 52 Week High
- TNXP $130.00
- VWAV $14.05
- Technical
- Relative Strength Index (RSI)
- TNXP 31.62
- VWAV N/A
- Support Level
- TNXP $18.53
- VWAV N/A
- Resistance Level
- TNXP $20.58
- VWAV N/A
- Average True Range (ATR)
- TNXP 1.09
- VWAV 0.00
- MACD
- TNXP 0.41
- VWAV 0.00
- Stochastic Oscillator
- TNXP 7.04
- VWAV 0.00
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.
About VWAV VisionWave Holdings Inc. Common Stock
VisionWave Holdings Inc is engaged in revolutionizing defense capabilities by integrating artificial intelligence (AI) and autonomous solutions across air, ground, and sea domains. Its innovations range from high-resolution radars and vision systems to radio frequency (RF) sensing technologies are seeking to redefine operational efficiency and precision for military and homeland security applications globally.